ADVANCED HEALTH LIMITED - Unaudited Condensed Consolidated Interim Financial Sstatements for the six months ended 31 December 2021

Unaudited Condensed Consolidated Interim Financial Sstatements for the six months ended 31 December 2021

ADVANCED HEALTH LIMITED
(Incorporated in the Republic of South Africa)
(Registration number 2013/059246/06)
(“the Company” or “Advanced”)
ISIN Code: ZAE000189049        JSE Code: AVL


 UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE
 SIX MONTHS ENDED 31 DECEMBER 2021


HIGHLIGHTS

    -   Profit after tax for the period is reported at R0.8 million (2020: (loss 9.8 million))
    -   Revenue decreased by 6% to R321.1 million (2020: R340.1 million).
    -   Cash generated from operations increased by 11% to R80.8 million (2020: R73.1 million).
    -   Basic loss per share improved by 3.1% to 2.81 cents (2020: basic loss per share of 2.90 cents).
    -   Headline loss per share increased by 30.1% to 2.81 cents (2020: headline loss per share of 2.16).

No dividend were proposed for the current period.

Short-form announcement
The contents of the short-form announcement are the responsibility of the Board of Directors of Advanced Health
Limited. The information in the short-form announcement is a summary of the full announcement and accordingly
does not contain full or complete details. The full announcement is available for inspection at no charge, Monday to
Friday, during office hours at the company’s registered office, the office of the Designated Advisor and on the
Company’s website on http://www.advancedhealth.co.za/ from 25 February 2022. The full announcement is available
on SENS from 25 February 2022 at https://senspdf.jse.co.za/documents/2022/jse/isse/AVL/DEC2021AVL.pdf.

The information in this announcement has been extracted from the unaudited condensed consolidated interim
financial statements for the six months ended 31 December 2021 and the short-form announcement itself has not
been reviewed by the Company’s auditors. Any investment decisions by shareholders/investors should be based on
the full announcement released to the JSE and published on the Company’s website.


CORPORATE INFORMATION
Advanced Health Limited                                        Registered Address:
(Incorporated in the Republic of South Africa)                 Building 2, Walker Creek Office Park
Registration number: 2013/059246/06                            90 Florence Ribeiro Avenue
ISIN: ZAE000189049 JSE Code: AVL                               Muckleneuk
                                                               0002
                                                               Postnet Suite 668, Private Bag X1
                                                               The Willows, 0041

 Executive directors                                            Non-Executive Directors
 GJ van Emmenis (Chief Executive Officer)                       FA van Hoogstraten (Lead Independent)
 MC Resnik# (Managing Director - Australia)                     CA Grillenberger (Chairman)
 D Goss-Ross (Managing Director - South Africa)                 PJ Jaffe #
 S Chonco (Chief Financial Officer)                             CJPG van Zyl
                                                               Dr WT Mthembu
                                                               YJ Visser
                                                               Dr KE Legodi

# Australian

Company Secretary:      M Janse van Rensburg
Auditors:               Mazars
Transfer Secretaries:   Link Market Services Proprietary Limited




Date of announcement: 25 February 2022
Designated Advisor
Grindrod Bank Limited

Date: 25-02-2022 02:30:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.